Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis

被引：0
作者：
Daiuske Ikuma
Masahiko Oguro
Junichi Hoshino
Hiroki Mizuno
Akinari Sekine
Masahiro Kawada
Rikako Hiramatsu
Keiichi Sumida
Eiko Hasegawa
Noriko Hayami
Masayuki Yamanouchi
Tatsuya Suwabe
Naoki Sawa
Kenmei Takaichi
Yoshifumi Ubara
机构：
[1] Nephrology Center,
[2] Toranomon Hospital,undefined
来源：
CEN Case Reports | 2020年 / 9卷
关键词：
Plaque psoriasis; Secukinumab; Hemodialysis and end stage renal disease (ESRD);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Secukinumab is effective to treat plaque psoriasis. However, the safety and efficiency of secukinumab have not been clarified in patients on hemodialysis. We report a 60-year-old Japanese woman. Plaque psoriasis was diagnosed at the age of 25 years and hemodialysis was started at the age of 39 years. Her skin lesions persisted despite use of topical agents such as maxacalcitol and betamethasone. Accordingly, administration of secukinumab was started at a dose of 150 mg. The psoriasis area and severity index (PASI) score decreased from 49.8 to 14.8 after 2 weeks and to 0 after 6 weeks, with remission being maintained after 28 months. No adverse reactions were seen. This case indicates that secukinumab may be effective for severe psoriasis in patients on hemodialysis for end-stage renal disease.
引用
收藏
页码：55 / 58
页数：3
相关论文
共 70 条
[1]  
Mease PJ(2015)Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis Curr Opin Rheumatol 27 127-133
[2]  
Paul C(2015)Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) J Eur Acad Dermatol Venereol 29 1082-1090
[3]  
Lacour JP(2015)Profile of secukinumab in the treatment of psoriasis: current perspectives Ther Clin Risk Manag 11 1767-1777
[4]  
Tedremets L(2002)Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients Am J Kidney Dis 39 571-579
[5]  
Kreutzer K(1978)Severe psoriasis–oral therapy with a new retinoid Dermatologica. 157 238-244
[6]  
Jazayeri S(2014)Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study J Dermatol 41 1039-1046
[7]  
Adams S(2010)Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial Journal of Dermatological Science 59 40-49
[8]  
Roman M(2010)Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study J Dermatol 37 299-310
[9]  
Madkan VK(2011)Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial The Journal of Dermatology 39 242-252
[10]  
Chiu MW(2006)Elimination mechanisms of therapeutic monoclonal antibodies Drug Discovery Today 11 81-88
1234567